Connect with us


Drugs from Bugs: Bioprospecting Insects to Fight Superbugs

(Credit: Yusnizam Yusof/Shutterstock)

Somewhat like looking down the barrel of a gun, antibiotic resistance is a looming threat to modern medicine. The rise of MRSA, super drug-resistant gonorrhea and other “nightmare” bacteria risk rendering our microscopic defenses useless. What to do when your last-last-last resort fails to kill these pathogens?

Someday, perhaps sooner than later, we’re going to need new antibiotics, not to mention medicines for cancer, depression, and other conditions that aren’t readily treatable by current prescriptions. So, how do we find new pharmaceuticals?

Some argue that we’ve reached “peak pharma,” but Ross Piper, an entomologist and research fellow at the University of Leeds, contends that we haven’t even begun looking. Our best bet may be beneath our feet, in the diminutive world of insects, and he says this research might also ignite conservation efforts.

“It could be a treasure trove of useful chemistry. Look at what compounds have been isolated from reptiles and snakes,” Piper said in a video call with Discover. His favorite example is exenatide, a synthetic hormone that treats diabetes mellitus type 2, originally derived from the saliva of Gila monsters. Between 2014 and 2016, sales of this drug reached $2.49 billion. “Who would have thought just by looking at the compounds in the saliva of a bloody lizard that you can produce a blockbuster drug for type 2 diabetes?”

For the past year, Piper has been engaged in what he calls “ecology-led drug discovery,” and he believes insects are the most promising lead. Bugs and other arthropods, awash in a tiny world of filth, need to protect themselves from disease, and have evolved many novel defenses.

While insect bioprospecting, as it’s called, is not entirely new, there’s much to be done. There’s an estimated 5.5. million different insect species on earth, but only around 20 percent have been described. Yet, entomologists are becoming scarce—so why isn’t bioprospecting bugs more popular?

Millions Of Insects, Millions Of Chemical Defenses

Humans have known about the medicinal benefits of compounds derived from insects—anti-bacterials, analgesics, anticoagulants, diuretics and antirheumatics—for hundreds, if not thousands, of years.

In a 2005 review, Eraldo Costa-Neto identified 64 different arthropod species from around 14 orders, all used medicinally by different cultures across five continents. In traditional Korean medicine alone, there are at least 19 insects and other arthropods commonly prescribed, including centipedes, cicada nymphal skins, and ghost moth larvae infected with the paralyzing fungus Ophiocordyceps sinensis.

More recently, scientists found that wasp venom can pop cancer cells while alloferon, a peptide isolated from the blood (hemolymph) of a species of blow fly, has antiviral and antitumor properties.

But one of the biggest problems is scaling. Once you find a chemical in something as tiny as a fly, how do you make sure you can make enough of it?

“Previously, you would have been restricted by not being able to find sufficient quantity of that particular species,” Piper says. “You maybe needed thousands of them to be able to extract enough of whatever that produces from whatever gland you’re looking at. But you can do that with much smaller quantities now.”

With advances in transcriptomics, not to mention all the buzz about CRISPR-Cas9, Piper believes we can isolate certain genes and insert them into the cell line of something else to mass-produce it. Alternatively, you could insert genetic material into other insects, such as crickets or mealworms, and mass-produce medicine this way.

“You could put vaccine genes or something like that, like they do in tobacco, into insects,” explains Aaron Dossey, an entomologist and pioneer in the insect-based food industry. He’s also the founder of All Things Bugs, a company that manufactures whole cricket powder. “Then use them as a mass production vehicle for your vaccine, your possible drug of choice or enzyme or bioactive peptide or some vitamin.”

Dossey suggests that stick insects or phasmids make “attractive model organisms for biosynthesis studies” due their large size and wide range of chemical defenses.

“Given the number of phasmid species analyzed…the number of novel compounds found in phasmids so far, and the total number of species in this order, phasmids represent a significant potential source of new compounds,” he wrote in a 2010 analysis.

Putting The Ant In Antibiotic

Among the most promising bugs to look for drugs are eusocial insects, especially in the order Hymenoptera — bees, wasps and ants. An anthill, which can contain hundreds of millions of workers with high genetic relatedness in compact, clustered living quarters, is the perfect place for disease outbreak.

“If one individual gets infected, a worker could spread it to thousands of individuals within a few hours,” says Clint Penick, an assistant research professor at Arizona State University who studies ant relationships. “Soil is the most by microbially dense and diverse habitat on the planet.” Therefore, ants need strong antimicrobials, which many species secrete from the metapleural glands on their back.

In research published in Royal Society Open Science in February, Penick and his colleagues tested the antimicrobial strength of 20 different ant species against Staphylococcus epidermidis, a common, generally benign, skin-dwelling bacteria. Using a vacuum-like device called a pooter, he collected ants from the sidewalk, in his backyard and on the way to work at North Carolina State University, where he was researching at the time.

“We hit all three of the major ant sub-families, which is a pretty good breadth of their diversity,” Penick says. Sixty percent of the ants tested inhibited bacterial growth, but efficacy was not dependent on colony population or even the size of the ant. In fact, one of the smallest ants tested—the thief ant, Solenopsis molesta—displayed the strongest antimicrobial properties.

The exact chemical properties behind these insects’ homegrown pharmacopeia is unknown. More research is needed to isolate these substances, but it’s getting easier all the time.

“What we developed was a method where you can measure a lot of ant species at once. We were able to run 96 samples in a day whereas other groups might be able to just run a couple dozen,” Penick says. “We’ve shown that we can scale this and look at more species. We’ve also narrowed down a little bit about which species might be interesting.”

No Rock Left Unturned

It’s easy to overlook some compounds because lab-grown insects often rely on native plants in their diet in order produce the same chemicals. For example, blister beetles, especially the so-called Spanish Fly, are noted for the extremely toxic cantharidin they produce. A terpene commonly used in wart cream, cantharidin has some anti-tumor properties, and can even potentially treat cardiac failure.

Male meloid beetles gift cantharidin to females, who in turn squirt it on their eggs to deter predators. They can make it themselves, but other so-called canthariphilous flies have to accumulate this blistering chemical by chomping on bastard teak, Butea frondosa, flowers or eating bugs that produce it.

Rove beetles also produce a vesicating toxin with potential antitumor properties called pederin, which they make using endosymbiotic bacteria that live in their hemolymph. Likewise, brown planthoppers make antibiotics using symbiotic bacteria.

So try to study these insects without the right diet or habitat and you may not find the same interesting chemicals, according to a 2010 analysis by Konrad Dettner, a now retired entomologist from the University of Bayreuth who specializes in the chemical ecology of insects.

“[W]hen bacteria or fungi were isolated from the insect hosts…in most cases these compounds have not even been shown to be present within the insect hosts,” he wrote. “Therefore, the biological significance of these natural compounds in symbiotic or parasitic systems where insects represent hosts is usually not known.”

This is partially why Piper argues that this type of research can benefit conservation efforts. Not only is preserving original habitats important for understanding chemical relationships, for every forest or swamp that is bulldozed into a Starbucks, there’s potentially billions of dollars worth of medications being destroyed. However, in his exenatide example, not a single cent of the billions generated from this hormone has gone back to preserve the home of the lizard where it was discovered.

“If you did find something and it was really successful, you could completely revolutionize the amount of cash available for conservation work,” Piper says. “We’re losing species that could have all sorts of potential applications. But then…you have to tread a fine line, because you can easily go down the road of putting a monetary value on things.”

Insects, it turns out, may be priceless.

Continue Reading
Click to comment


We've Been Putting A Potentially Dangerous, Drug-resistant Yeast in Food for Centuries

A block of fresh yeast. (Credit: avs/Shutterstock)

You say to-MAY-to, I say to-MAH-to. You say po-TAY-to, I say po-TAH-to. You say Candida krusei, I say Pichia kudriavzevii — and that should make you a little nervous.

OK, so that last bit needs explaining. C. krusei is a drug-resistant yeast species that’s responsible for thousands of potentially fatal infections in the United States every year. P. kudriavzevii is a yeast species that’s been widely used for centuries in the food industry and is playing a larger role in the production of bioethanol and other chemicals.

C. krusei and P. kudriavzevii, two very different names, playing two very different roles … uhh, yeeeaaah, scientists have confirmed they’re the same species.

Indeed, we’ve been given the ole’ Jekyll-and-Hyde treatment, which means we’ve been using a drug-resistant strain of yeast, capable of infecting human beings, on an industrial scale for centuries. This little truth bomb comes courtesy of a team of researchers led by Alexander Douglass at the University College Dublin in Ireland.

A Yeast by Many Names

Yeast of the Candida species cause roughly 46,000 fungal infections in the U.S. every year, with a 30 percent mortality rate — the ebola virus hovers around 50 percent, by comparison. Candida yeasts actually reside in the intestines and can be found on the skin and mucous membranes. The trouble starts when these yeasts begin to multiply at far higher rates than normal, especially if they enter the bloodstream. Candida infections pose a particular threat to people with weakened immune systems.

The most notorious among the Candida gang of yeasts is C. albicans, which is the culprit behind more than half the annual Candida infections in the U.S. C. krusei, the yeast featured in this study, is only responsible for about 2 percent of infections. Still, you wouldn’t put C. krusei at the top of your ingredients list for your next meal.

But that’s exactly what we’ve been doing by using P. kudriavzevii around the world in fermented beverages, milk and biofuels.

Taxonomists Knew It

Yeast taxonomists back in 1980 proposed that C. krusei and P. kudriavzevii were the same species, but the theory was difficult to prove and the information didn’t trickle out to other scientists. And for decades, the yeast’s dual identity split the research community into two fronts, says Ken Wolfe, a UCD geneticist and co-author on the study.

“There are basically two separate communities of scientists working on this organism, publishing papers about it but calling it different names, which led to very poor communication and ignorance about each other’s work,” Ken Wolfe, a UCD geneticist and co-author on the study wrote in an email to Discover. “The medical people called it C. krusei, and the food/biotech people called it P. kudriavzevii.”

Because of the split, research comparing the genetic similarities of P. kudriavzevii and C. krusei was lacking. There had never been an analysis comparing the environmental and clinical strains of these two (well, one) yeast species.

So, Douglass and his team sequenced the genomes of 30 different strains of both yeast species. They found the strains share genomes that are 99.6 percent identical in DNA sequence. Researchers say that’s pretty conclusive evidence that they are the same. Douglass and his team published their findings Thursday in the journal PLOS Pathogens. Wolfe believes scientists would have arrived at this conclusion far sooner had the wider scientific community been privy to what the taxonomists already knew.

Now What?

How concerned is Wolfe about all of this? He’s at about a 3 on a scale of 1-10.

“This yeast only causes infections in immunocompromised people, such as organ transplant recipients or an AIDS patient,” says Wolfe. “People with healthy immune systems need not be concerned.”

You’ll find P. kudriavzevii in some craft beers, sourdough breads and pickled vegetables. Therefore, Wolfe would advise people with weak immune systems to avoid craft beer and pickles. The yeast poses a particular problem for organ transplant recipients because they are treated continuously with a drug known as fluconazole to prevent fungal infections.

“If these patients do get a fungal infection, it tends to be with a fluconazole-resistant species such as P. kudriavzevii. So for these patients, eating foods that contain P. kudriavzevii seems inadvisable,” says Wolfe.

The Centers for Disease Control and Prevention considers Candida fungal infections a growing threat, given that they are resistant to the fluconazole antifungal treatment. The C.D.C. considers anotherr strain in particular, C. auris, an emerging global threat. It’s causing infections and hospitalizations around the world, and is resistant to multiple forms of treatment.

Douglass says their research is a starting point, and should serve as a resource for ongoing investigations. It’s an earnest invitation for more researchers to examine these yeast strains a little closer, and perhaps rethink how we use them in future applications.

“I think it would be appropriate for regulators to make spot-checks on the food products, particularly to check that the P. kudriazeii strains they contain are not resistant to other drugs as well as fluconazole,” says Wolfe. “We found that some environmental strains of P. kudriazeii were relatively resistant to other drugs too.”

Continue Reading


The Curious Case of Acrylamide: California’s Prop. 65 Explained

(Credit: M. Unal Ozmen/Shutterstock)

Most of us think of coffee as a morning essential, not a cancer-causing hazard. So the nation got a jolt after a California judge made a final ruling in May that Starbucks and other coffee sellers must inform customers about carcinogenic chemicals in their brews.

The ruling stemmed from a court case invoking Proposition 65, a state law that requires warnings if products or places contain certain types of hazardous chemicals. But the implications reach far beyond the Golden State. California has the sixth-largest economy in the world, so manufacturers of consumer goods worldwide try to abide by Prop. 65 regulations.

Here’s a primer on how hazardous chemicals get listed and regulated, the ongoing coffee case — yes, it’s still not over — and what might be labeled or litigated next.

Why will there be signs next to Starbucks registers warning that coffee contains chemicals that cause cancer and birth defects?

In late March, a Los Angeles Superior Court judge ruled that cups of coffee sold to consumers would fall under the Safe Drinking Water and Toxic Enforcement Act — Prop. 65 — which was passed by a ballot vote of California residents in 1986. The judge made a final ruling May 7.

The law applies because roasted coffee beans — and beverages brewed from them — contain acrylamide, which is on Prop. 65’s state-regulated list of chemicals “known” to cause cancer, birth defects or reproductive harm. If a product contains any of the list’s approximately 900 chemicals, it must be labeled to warn consumers, or the chemical must be removed or reduced to levels that Prop. 65 regulators consider safe.

In April 2010, an organization called the Council for Education and Research on Toxics (CERT), which is located at the same address as the Long Beach law firm that represented it and that specializes in litigating such cases, sued about 160 companies, including Starbucks Corp. and the convenience store 7-Eleven, to force them to label their coffee with Prop. 65 warnings. The Los Angeles judge ruled that companies failed to demonstrate that the health benefits of coffee outweighed the risks posed by acrylamide, which include cancer and developmental and reproductive harm. 7-Eleven and some other companies have already settled out of court, agreeing to pay fines and place warning signs at the point of sale.

What does a Prop. 65 warning say and mean?

Up till now, generally words along the lines of: “WARNING: This product/area contains chemicals known to the State of California to cause cancer and birth defects or other reproductive harm. For more information go to”

Such signs on a product, or in a restaurant, workplace, living space or parking garage, mean that the product or environment contains a chemical on the Prop. 65 list. A business must give “clear and reasonable warning” if knowingly exposing anyone, unless it can show the exposure falls under “safe harbor” levels: amounts determined by the state to pose no significant risk. (California set acrylamide’s safe harbor levels for cancer risk at 0.2 micrograms per day — its estimation of a dose that would risk cancer developing in 1 in 100,000 people, based on laboratory rat data. It set the level for reproductive risk at 140 micrograms per day.)

Proposition 65 warnings, like this one at Disneyland, have generally been very vague. New laws will require that the warnings name specific chemicals and their sources. CREDIT: PATRICK PELLETIER / WIKIMEDIA COMMONS

Proposition 65 warnings, like this one at Disneyland, have generally been very vague. New laws will require that the warnings name specific chemicals and their sources. (Credit: Patrick Pelletier/Wikimedia Commons)

How does acrylamide end up in foods?

The chemical naturally forms in items such as baked goods, cereals, potato products and coffee during the Maillard, or browning, reaction, when the amino acid asparagine and a sugar combine in the presence of heat higher than 120 degrees Celsius (248°F).

“Any time you heat-process a food — toast a piece of bread, fry potatoes, bake a crust — sugars react with amino acids to form a whole catalog of chemicals. Acrylamide happens to be one of those chemicals,” says James Coughlin, a chemist in Aliso Viejo, California, and an independent consultant for the food industry. (Coughlin has consulted for the National Coffee Association and Starbucks in the past but is not currently working for any companies in the California court case.)

Acrylamide forms when bread is toasted and the amino acid asparagine reacts with sugars at high heat. CREDIT: MILOS LUZANIN / SHUTTERSTOCK

Acrylamide forms when bread is toasted and the amino acid asparagine reacts with sugars at high heat. (Credit: Milos Luzanin/Shutterstock)

When green coffee beans are roasted (typically at 180° to 240°C for about 15 minutes), more than 1,000 chemical compounds result as different sugars and amino acids combine and break down. “Coffee is the best example of the browning reaction gone wild,” Coughlin says. That swirl of chemicals gives coffee its complex tastes and aromas.

What is the evidence that acrylamide causes cancer or reproductive harm?

Acrylamide is used in industry and research to make polymers and is a neurotoxin at very high doses. It was found to be present in starchy, browned foods in 2002.

For cancer studies in 1986 and 1995, researchers fed rats high doses of acrylamide in their drinking water throughout their two-year lifetime. The highest doses increased rates of thyroid, testicular and breast tumors. In 2012, the US government’s National Toxicology Program (NTP), which tests environmental chemicals for potentially hazardous health effects, found similar increases in rats and mice. In male rats, the rate of thyroid tumors rose from 6 percent in rats fed no acrylamide to 25 percent in those fed the highest dose, for example. In females, the rate of a breast tumor rose from 33 percent without acrylamide to 65 percent for the highest dose.

(The NTP also assessed for reproductive harm in 2005 and found that while acrylamide causes slight increases in the incidence of low birth weight and less effective sperm in mice and rats fed high doses, there was no evidence that acrylamide exposure in people results in adverse reproductive effects.)

But experts say that the carcinogenicity of acrylamide in people is still up for debate. For one thing, says Coughlin, doses fed to rodents in these studies were extremely high — the equivalent of a 150-pound person drinking 11,000 to 136,500 eight-ounce cups of coffee per day. For another, population studies of workplace exposure to acrylamide have not found dose-related increases in any specific cancer or in overall cancer mortality.

An analysis of 25 epidemiology studies, encompassing 39,476 people, found no increased risk for 15 types of cancer when comparing people with average dietary intakes of acrylamide to those with daily intakes 10 micrograms higher (the amount in five eight-ounce cups of coffee). The authors concluded that dietary levels of acrylamide do not pose an increased risk of most types of cancer.

How do chemicals get on the Prop. 65 list?

In four ways. A chemical is automatically added if listed as a carcinogen or a developmental or reproductive toxicant by any of five authoritative bodies — the National Toxicology Program and three other US agencies, or the World Health Organization’s International Agency for Research on Cancer (IARC). It only takes one agency to spark a listing; in the case of acrylamide, all five agencies list it as a probable human carcinogen.

A chemical may also be added if the California Labor Code deems it a cancer or reproductive risk, or if another agency requires a label. And it can be added if California-appointed State Qualified Experts — committees of researchers who specialize in cancer or developmental and reproductive biology — review the science and declare a chemical harmful by a majority vote.

Processed meats such as sausages were listed in 2015 by the International Agency for Research on Cancer as “carcinogenic to humans,” based on population studies that reported slightly increased rates of colorectal cancer in people who consumed the meats. Some speculate that processed meats will soon be added to Proposition 65's list of chemicals. (Credit: Joshua Resnick/Shutterstock)

Processed meats such as sausages were listed in 2015 by the International Agency for Research on Cancer as “carcinogenic to humans,” based on population studies that reported slightly increased rates of colorectal cancer in people who consumed the meats. Some speculate that processed meats will soon be added to Proposition 65’s list of chemicals. (Credit: Joshua Resnick/Shutterstock)

That can be a tough call because the data are often imperfect, says toxicologist David Eastmond of the University of California, Riverside, a member of the Carcinogen Identification Committee. It bothers him that even if committees have reviewed a chemical and deemed it safe, another agency can override that work. “It’s not real often that you have differences,” he says. “But it makes you wonder, are you doing something consistent?”

Acrylamide was added to the Prop. 65 list in 1990 because both the IARC and the US Environmental Protection Agency (another of the triggering bodies) listed it as a carcinogen based on animal studies.

Are chemicals ever taken off the list?

Yes. Several have been delisted after studies showed them not to be carcinogens or reproductive toxins. (A reassessment can be triggered by State Qualified Experts, a state agency or petition by a member of the public.) One notable case is the artificial sweetener saccharin, which was listed as a carcinogen in 1989 because it caused bladder cancer in rodent studies, and was delisted in 2001. Decades of research showed that the way saccharin caused bladder cancer in male rats was not possible in humans.

Why are items listed when they might not be harmful to people?

The statute is designed to be precautionary and protective, says Claudia Polsky, director of the Environmental Law Clinic at UC Berkeley Law. “If it’s possible to decrease the levels of acrylamide in coffee, then people will have a lower exposure over their lifetime of a probable carcinogen,” she says. And the regulation, she adds, forces industry to innovate to find ways to remove or reduce harmful chemicals.

“Drinking coffee is still fine, and possibly even good for you,” she says. “But thanks to Prop. 65, coffee manufacturers might be able to make it even better.”

So is it safe to drink coffee or not?

The Food and Drug Administration, the European Food Safety Authority and Health Canada have all ruled coffee safe to drink, except for pregnant women, who should limit their intake.

A review of more than 100 epidemiology studies encompassing more than 21 million people found that coffee consumption has an overall health benefit, decreasing risks for a variety of diseases including cardiovascular disease, type II diabetes, Parkinson’s disease and several cancers.

Coughlin says that roasted coffee beans or their grounds contain about 450 micrograms of acrylamide per kilogram, but brewed coffee contains only about 10 to 30 — a tiny dose compared to eating french fries or potato chips, which can contain acrylamide in the thousands of micrograms. The amount in an eight-ounce cup of coffee, 2 micrograms, is ten times the state’s safe harbor level of 0.2 micrograms a day. Acrylamide reacts with other proteins in the body as soon as it is absorbed, Coughlin adds, and is also detoxified by an enzyme called glutathione transferase.

Saccharin, found in products such as Sweet'N Low, was removed from Proposition 65’s list of risky chemicals in 2001. Decades of research showed it did not pose a cancer risk in people. (Credit: elbud/Shutterstock)

Saccharin, found in products such as Sweet’N Low, was removed from Proposition 65’s list of risky chemicals in 2001. Decades of research showed it did not pose a cancer risk in people. (Credit: elbud/Shutterstock)

“The bottom line for coffee is that while it does contain a small dose of acrylamide along with several other animal carcinogens, the overall beverage is loaded with antioxidants and has been shown to reduce the risk of several cancers,” he says.

Could it be made safer?

Maybe. After potato chip and french fry makers were sued by the California attorney general in 2005, they found ways to reduce acrylamide levels. Potatoes can be blanched to reduce sugar content, treated with an enzyme to remove much of the asparagine, or cooked for less time or at lower temperatures.

But coffee is trickier. Coffee company scientists say they have tried to reduce acrylamide levels by altering roasting times or steaming, but achieved only modest reductions and distorted the brew’s flavor and aroma.

Does Prop. 65 do a good job of protecting people from harmful chemicals?

Polsky and others who support the law point to Prop. 65’s successes: Coke and Pepsi removed 4-methylimidazole, a carcinogen in caramel coloring, from their sodas; companies have removed lead, a potent developmental toxin, from children’s jewelry, wine bottle caps and candy imported to the United States from Mexico. Target and CVS pharmacies have pledged to remove phthalates and formaldehyde from cosmetics and personal-care products due in part to pressure from the law.

But some worry that the sheer number of Prop. 65 warning signs seen in parking garages, auto mechanic shops, dentist’s and doctor’s offices and coffee shops erodes their clout. “Are you unduly frightening the public or are you posting warnings so often that people ignore them?” asks Eastmond. “Coffee and acrylamide might be one of those cases where we are warning someone about something that’s not really a serious health concern.”

Megan Schwarzman, an environmental health scientist and physician at the UC Berkeley School of Public Health, agrees that the media spotlight on what looks like an absurd coffee warning could undermine the law’s effectiveness and overshadow cases where it has compelled large companies to remove or reduce truly dangerous chemicals.

And Schwarzman, Coughlin and Eastmond all point to one major failing of the law: It does not take into account the doses that were used in toxicology studies when deciding to list a chemical. People drinking coffee — even large amounts daily — do not come remotely close to the concentrations that caused harm in animal tests.

There hasn’t been a scientific evaluation of the law’s effectiveness to date. But Schwarzman, Polsky and a team of researchers are taking the first systematic look at whether Proposition 65 has been effective in one particular arena: reducing exposure of Californians to chemicals associated with breast cancer, such as endocrine disruptors, phthalate plasticizers and diesel exhaust.

Could Prop. 65 be improved?

Experts agree that there’s room for improvement in the way the statute is written and enforced.

One major criticism is that Prop. 65 warnings are too generic to be useful. Until now, signs usually have not noted which chemicals are present or whether people are at risk from, say, just walking to and from a parked car in a garage. Nor do they distinguish between high, medium and low risks. Warnings, Schwarzman says, should “only exist for significant public health risks.”

New rules taking effect in August will require inclusion of names of specific chemicals and their source.

Another criticism is that the law has become a cash cow for law firms seeking to force companies into settlements. In 2015, $26 million was paid in Prop. 65 settlements, of which nearly $18 million, or 68 percent, went toward plaintiff attorney fees. In 2016, the California attorney general’s office, which enforces Prop. 65, changed how settlements could be made in Prop. 65 lawsuits brought by private plaintiffs. The aim was to limit the portion of settlements that could go to plaintiffs and ensure that the state got its fair share of civil penalties. There still is no limit on how much of a settlement can go toward paying plaintiff attorney fees.

In another ongoing Prop. 65 court case, a judge ruled that the herbicide chemical glyphosate did not have to be labeled. Why not?

Glyphosate is a chemical found in the widely popular herbicide Roundup, produced by the company Monsanto.

Of the five triggering agencies, only the World Health Organization’s IARC has classified the chemical as a “probable human carcinogen.” The other four say it has low toxicity and does not pose a risk. Glyphosate went on the Prop. 65 list in July 2017.

The IARC is the most precautionary of the five triggering agencies, and works only with published data. In situations where much of the research is proprietary, that can be an issue, Eastmond says. He says he has seen the extensive unpublished data on glyphosate toxicology in rats, and epidemiology in exposed farm workers, and believes that the IARC very likely would not have reached the conclusion it did if it had reviewed those data too.

Monsanto does not want glyphosate regulated under Prop. 65 and sued the state of California in federal court in November 2017 to prevent a labeling requirement. A judge ruled in February that since only one agency had found glyphosate a possible carcinogen, the company could not be compelled to label its product as “known to cause cancer”; that would be compelled speech and could mislead a reasonable consumer. Glyphosate remains on the Prop. 65 list, but the judge temporarily barred the state from enforcing the warning requirement.

Neither the coffee nor the glyphosate case is settled. Some of the coffee companies may appeal after the final judgment of the penalty phase of that case is decided this summer or later, and the glyphosate ruling is just a “preliminary injunction” as that case proceeds.

What lawsuits might come next?

Prop. 65 lawsuits are scattershot and hard to predict, but there are clues. In the first week of May alone, private citizens filed 29 notices of violation with the California attorney general’s office seeking to sue companies for Prop. 65 violations. The complaints target items like phthalates in cosmetics, acrylamide in almonds and lead in dietary supplements. The notified companies include CVS pharmacies, Trader Joe’s and Nordstrom.

What might be listed next?

Processed meats — such as bacon and hot dogs — were listed in 2015 by the IARC as “carcinogenic to humans.” The agency listed red meat as “probably carcinogenic to humans” (the same category as acrylamide) because the evidence was more limited. Both listings, finalized in March, were based on epidemiological studies of colorectal cancer, which showed slightly increased risks associated with processed meat and red-meat consumption.

Coughlin suspects that this will trigger California to add processed meats to the Prop. 65 list. Interestingly, after facing public uproar in 2015, the WHO released a statement that processed meats were still part of a healthy diet.

This article originally appeared in Knowable Magazine, an independent journalistic endeavor from Annual Reviews. Sign up for the newsletter.

Knowable Magazine | Annual Reviews

Continue Reading


New Detector Brings X-ray Scans Into Living Color For the First Time

A 3D image of a wrist with a watch showing part of the finger bones in white and soft tissue in red. (Image: MARS Bioimaging Ltd)

Like Dorothy coming to Oz, doctors might finally be experiencing their world in color.

A new scanner, using technology developed by CERN for detecting subatomic particles, can produce color X-ray scans of the inside of the body, allowing doctors to see soft tissues in unprecedented detail. The technology is set for clinical trials in New Zealand soon.

X-ray Upgrade

Normal X-rays illuminate our insides in shades of grey — hard tissues like bone are white and soft tissues are black. That’s because normal detectors only read whether the x-rays are coming through or not. Bone blocks X-rays, so they show up as white; soft tissues don’t, so they’re black.

The new detector was made by New Zealand-based company Medipix. Their tech is based on detectors used by the Large Hadron Collider for measuring particles created by protons smashing together at nearly the speed of light. And it can pick out subtle changes in the energy levels of the incoming X-rays to tell a more detailed story about the types of tissues it passes through. Muscle, fat, connective tissues and more all alter the x-rays in different ways, and the new detector picks up on that.


Paired with algorithms specialized for putting this information together and spitting it back out as cohesive images, doctors can now see a 3-dimensional view of the body where each type of tissue stands out distinctly. The colors themselves aren’t necessarily “true” color — they’re added in afterwards to distinguish various tissue types — but they do give doctors much more information from a standard x-ray scan than before. The technology could conceivably be used to search for tumors, assess bone and joint health and provide updates on vascular health, among other things.

That’s pending clinical safety trials, of course, but the technology does offer essentially an upgrade to an existing technique, which might help smooth the process along. It’s a positive for doctors, though for the rest of us who might not enjoy seeing the insides of our bodies in high-resolution, well, we might just have to look away.

Continue Reading


@RuggieriJoe @gblondon1 I stopped using apps about 6 weeks ago Joe (never used gett). Been doing plenty,and I keep all the fare and tips. #parasites

Intestinal parasite cases spiking in Illinois also hitting Rock River Valley ⁦@IDPH⁩ ⁦@WinnCountyNews#parasites…


A combination regimen comprised of #azithromycin & #ivermectin is associated w/ similar reductions in #scabies & #impetigo compared w/ #ivermectin monotherapy in communities w/ high rates of these infections

test Twitter Media - A combination regimen comprised of #azithromycin & #ivermectin is associated w/ similar reductions in #scabies & #impetigo compared w/ #ivermectin monotherapy in communities w/ high rates of these infections

Adding #azithromycin to #ivermectin does not improve impetigo, scabies treatment

Treatment with #azithromycin plus #ivermectin versus ivermectin alone provides equal protection against #scabies & #impetigo in at-risk communities, new @LSHTM study finds

test Twitter Media - Treatment with #azithromycin plus #ivermectin versus ivermectin alone provides equal protection against #scabies & #impetigo in at-risk communities, new @LSHTM study finds